Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ziprasidone
Drug ID BADD_D02415
Description Disorders such as schizophrenia and bipolar disorder can significantly impair mood, cognition, and behavior.[A190525] These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers.[A190525] Luckily, several treatment options for psychotic disorders have been introduced to market since the realization of chlorpromazine's antipsychotic properties in 1952.[A190525] Second generation antipsychotics (commonly referred to as atypical antipsychotics) include [clozapine], [quetiapine], [olanzapine], [aripiprazole] and [ziprasidone] among others, and are generally thought to be as efficacious as first generation antipsychotics but differ in their adverse effect profiles.[A190525,A190534] First generation antipsychotics are associated with extrapyramidal adverse effects while atypical antipsychotics are linked to weight gain, impaired glucose tolerance and metabolic syndrome.[A190534,A190537] Ziprasidone is used to treat schizophrenia and bipolar disorder.[A180748] It can effectively reduce the rate and time of relapses in schizophrenia, and can be used to treat manic episodes in bipolar disorder although the mechanism of action is unknown.[A180748] Although ziprasidone is classified as an atypical antipsychotic, it appears to have a lower incidence of metabolic adverse effects compared to other medications in the same class.[A190525]
Indications and Usage In it's oral form, ziprasidone is approved for the treatment of Schizophrenia and Bipolar I disorder while the injectable formulation is approved for treatment of acute agitation in schizophrenia.
Marketing Status Not Available
ATC Code N05AE04
DrugBank ID DB00246
KEGG ID D08687
MeSH ID C092292
PubChem ID 60854
TTD Drug ID D0R1JV
NDC Product Code 72578-023; 70771-1182; 57297-330; 59762-1006; 0049-0358; 0049-0356; 0049-0352; 72578-021; 70771-1179; 70771-1181; 72578-020; 72578-022; 70518-3376; 70771-1180
Synonyms ziprasidone | ziprazidone | 5-(2-(4-(3-benzisothiazolyl)piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one | ziprasidone hydrochloride | CP 88059-01 | CP-88,059-1 | CP-88,059-01 | ziprasidone hydrochloride, monohydrate | Geodon | CP 88059 | CP-88,059
Chemical Information
Molecular Formula C21H21ClN4OS
CAS Registry Number 146939-27-7
SMILES C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abortion18.01.01.0010.002746%Not Available
Agitation19.06.02.001; 17.02.05.0120.005491%
Akathisia19.06.02.006; 17.01.02.0020.001830%
Altered state of consciousness19.07.01.003; 17.02.04.0010.002746%Not Available
Alveolitis allergic22.01.01.002; 10.01.03.0080.005491%Not Available
Anxiety19.06.02.0020.004576%
Blood creatine phosphokinase increased13.04.01.0010.003661%
Blood pressure increased13.14.03.0050.001830%Not Available
Bradycardia02.03.02.0020.001830%Not Available
Cardiac arrest02.03.04.0010.001910%
Cardio-respiratory arrest02.03.04.002; 22.02.06.0070.000955%Not Available
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.0110.001830%Not Available
Coma17.02.09.0010.001830%Not Available
Completed suicide19.12.01.001; 08.04.01.0100.002865%Not Available
Confusional state17.02.03.005; 19.13.01.0010.001830%
Coordination abnormal17.02.02.0040.001830%Not Available
Cough22.02.03.0010.002746%
Death08.04.01.001--
Delusion19.10.01.0010.003661%
Diarrhoea07.02.01.001--
Discomfort08.01.08.0030.001830%Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.0040.003661%
Drug abuse19.07.02.0100.000478%Not Available
Drug hypersensitivity10.01.01.0010.010067%Not Available
Drug withdrawal syndrome19.07.02.011; 08.06.02.0040.001830%Not Available
Dysphagia07.01.06.0030.006407%
Dyspnoea22.02.01.004; 02.01.03.0020.004576%
Dystonia17.01.03.0010.006407%Not Available
Electrocardiogram QT prolonged13.14.05.0040.005491%
Embolism venous24.01.01.0030.000716%Not Available
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages